Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Capucine Baldini

Showing results (41-50 of 101) with videos related to

Pageof 11
Sort By:
Cancer Medicine|February 20, 2020
Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor typesPatricia Martin-Romano, Eduardo Castanon, Samy Ammari, et al.
Expert Review of Anticancer Therapy|July 11, 2022
Immunosenescence, inflammaging, and cancer immunotherapy efficacyJulieta E Rodriguez, Marie Naigeon, Vincent Goldschmidt, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2021
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registryValentine Ruste, Vincent Goldschmidt, Ariane Laparra, et al.
Cancers|October 27, 2022
Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI ScoreMonica Pierro, Capucine Baldini, Edouard Auclin, et al.
International Journal of Radiation Oncology, Biology, Physics|August 11, 2024
Is Local Ablative Stereotactic Radiation Therapy a Valuable Rescue Strategy for Time on Drug in Patients Enrolled in Phase I Trials?Antoine Mavrikios, Capucine Baldini, Yohann Loriot, et al.
European Journal of Cancer (Oxford, England : 1990)|April 4, 2022
Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugsEmeline Guiard, Capucine Baldini, Cédric Pobel, et al.
European Journal of Cancer (Oxford, England : 1990)|August 22, 2017
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)Roger Sun, Stéphane Champiat, Laurent Dercle, et al.
European Journal of Cancer (Oxford, England : 1990)|May 13, 2023
Profile and outcome of cancer patients enrolled in contemporary phase I trialsEmily Alouani, Anas Gazzah, Sandrine Mercier, et al.
Journal of Geriatric Oncology|September 8, 2023
Rethinking care management for older adults with cancer: Proposals from the "PRIORITES AGE CANCER" French groupAngéline Galvin, Nicolas Bertrand, Rabia Boulahssass, et al.
Bulletin Du Cancer|May 22, 2022
[Rethinking the management of elderly cancer patients : Proposals from the Age Cancer Priorities French Group]Angéline Galvin, Nicolas Bertrand, Rabia Boulahssass, et al.
Pageof 11

Showing results (41-50 of 101) with videos related to

Sort By:
Pageof 11
Cancer Medicine|February 20, 2020
Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor typesPatricia Martin-Romano, Eduardo Castanon, Samy Ammari, et al.
Expert Review of Anticancer Therapy|July 11, 2022
Immunosenescence, inflammaging, and cancer immunotherapy efficacyJulieta E Rodriguez, Marie Naigeon, Vincent Goldschmidt, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2021
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registryValentine Ruste, Vincent Goldschmidt, Ariane Laparra, et al.
Cancers|October 27, 2022
Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI ScoreMonica Pierro, Capucine Baldini, Edouard Auclin, et al.
International Journal of Radiation Oncology, Biology, Physics|August 11, 2024
Is Local Ablative Stereotactic Radiation Therapy a Valuable Rescue Strategy for Time on Drug in Patients Enrolled in Phase I Trials?Antoine Mavrikios, Capucine Baldini, Yohann Loriot, et al.
European Journal of Cancer (Oxford, England : 1990)|April 4, 2022
Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugsEmeline Guiard, Capucine Baldini, Cédric Pobel, et al.
European Journal of Cancer (Oxford, England : 1990)|August 22, 2017
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)Roger Sun, Stéphane Champiat, Laurent Dercle, et al.
European Journal of Cancer (Oxford, England : 1990)|May 13, 2023
Profile and outcome of cancer patients enrolled in contemporary phase I trialsEmily Alouani, Anas Gazzah, Sandrine Mercier, et al.
Journal of Geriatric Oncology|September 8, 2023
Rethinking care management for older adults with cancer: Proposals from the "PRIORITES AGE CANCER" French groupAngéline Galvin, Nicolas Bertrand, Rabia Boulahssass, et al.
Bulletin Du Cancer|May 22, 2022
[Rethinking the management of elderly cancer patients : Proposals from the Age Cancer Priorities French Group]Angéline Galvin, Nicolas Bertrand, Rabia Boulahssass, et al.
Pageof 11